Stock Price Quote

TATVA CHINTAN PHARMA CHEM LTD.

NSE : TATVABSE : 543321ISIN CODE : INE0GK401011Industry : ChemicalsHouse : Private
BSE1079.555.15 (+0.48 %)
PREV CLOSE ( ) 1074.40
OPEN PRICE ( ) 1078.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 15310
TODAY'S LOW / HIGH ( )1063.35 1085.15
52 WK LOW / HIGH ( )1063.35 1888.05
NSE1078.601.1 (+0.1 %)
PREV CLOSE( ) 1077.50
OPEN PRICE ( ) 1077.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1078.60 (10)
VOLUME 98429
TODAY'S LOW / HIGH( ) 1061.35 1089.40
52 WK LOW / HIGH ( )1061.35 1887.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-06 1996
Management Info
Chintan Nitinkumar Shah - Chairman Chintan Nitinkumar Shah - Managing Director
Registered Office

Address Plot No 502/17,G I D C Estate,Ankleshwar,
Bharuch,
Gujarat-393002

Phone 07574848533 / 34

Email chintan@tatvachintan.com

Website www.tatvachintan.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

16Mar Tatva Chintan Pharma Chem submits anal
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
27Jan Tatva Chintan Pharma Chem informs abou
Pursuant to Securities and Exchange Board of India (Listing Obligations..
17Jan Tatva Chintan Pharma Chem informs abou
Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure..
08Sep Tatva Chintan Pharma Chem informs abou
Tatva Chintan Pharma Chem has informed that the Exchange has received th..
07Sep Tatva Chintan Pharma Chem informs abou
Tatva Chintan Pharma Chem has informed about filing of Report under Regu..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit46.51404.649999999999
Gross Profit 65.63 388.309999999999
Operating Profit 135.22603.559999999999
Net Sales 860.694030.44

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Polson (BSE)
peergroup  12645.60 (2.05%)
M.Cap ( in Cr)151.75
GOCL Corporation (BSE)
peergroup  453.35 (20.00%)
M.Cap ( in Cr)2247.37
Polychem (BSE)
peergroup  2416.15 (1.66%)
M.Cap ( in Cr)97.62
SRF (BSE)
peergroup  2557.55 (1.38%)
M.Cap ( in Cr)75812.13
Sree Rayal.Hi-Strent (BSE)
peergroup  491.90 (5.55%)
M.Cap ( in Cr)844.34

Shareholding Pattern

PROMOTERS 72.02%
MUTUAL FUNDS/UTI 13.05%
NON-INSTITUTION 10.71%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Tatva Chintan Pharma Chem Ltd.

Tatva Chintan Pharma Chem Ltd. was incorporated in the year 1996. Its today's share price is 1079.55. Its current market capitalisation stands at Rs 2525.29 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4041.09 Cr and Total Income of Rs.4087.22 Cr. The company's management includes Ishwar Nayi, Avani Rajesh Umatt, Subhash Ambubhai Patel, Manher Chimanlal Desai, Shekhar Rasiklal Somani, Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, Chintan Nitinkumar Shah.

It is listed on the BSE with a BSE Code of 543321 , NSE with an NSE Symbol of TATVA and ISIN of INE0GK401011. It's Registered office is at Plot No 502/17,G I D C Estate,AnkleshwarBharuch-393002, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are NDJ & Co, Pathak Anjaria & Co.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.